Literature DB >> 34253877

Hepatic Vps33b deficiency aggravates cholic acid-induced cholestatic liver injury in male mice.

Kai-Li Fu1, Pan Chen2, Yan-Ying Zhou1, Yi-Ming Jiang1, Yue Gao1, Hui-Zhen Zhang1, Li-Huan Guan1, Cong-Hui Wang3, Jun-Ling Liu3, Min Huang1, Hui-Chang Bi4.   

Abstract

Vacuolar protein sorting 33B (VPS33B) is important for intracellular vesicular trafficking process and protein interactions, which is closely associated with the arthrogryposis, renal dysfunction, and cholestasis syndrome. Our previous study has shown a crucial role of Vps33b in regulating metabolisms of bile acids and lipids in hepatic Vps33b deficiency mice with normal chow, but it remains unknown whether VPS33B could contribute to cholestatic liver injury. In this study we investigated the effects of hepatic Vps33b deficiency on bile acid metabolism and liver function in intrahepatic cholestatic mice. Cholestasis was induced in Vps33b hepatic knockout and wild-type male mice by feeding 1% CA chow diet for 5 consecutive days. We showed that compared with the wild-type mice, hepatic Vps33b deficiency greatly exacerbated CA-induced cholestatic liver injury as shown in markedly increased serum ALT, AST, and ALP activities, serum levels of total bilirubin, and total bile acid, as well as severe hepatocytes necrosis and inflammatory infiltration. Target metabolomics analysis revealed that hepatic Vps33b deficiency caused abnormal profiles of bile acids in cholestasis mice, evidenced by the upregulation of conjugated bile acids in serum, liver, and bile. We further demonstrated that the metabolomics alternation was accompanied by gene expression changes in bile acid metabolizing enzymes and transporters including Cyp3a11, Ugt1a1, Ntcp, Oatp1b1, Bsep, and Mrp2. Overall, these results suggest a crucial role of hepatic Vps33b deficiency in exacerbating cholestasis and liver injury, which is associated with the altered metabolism of bile acids.
© 2021. The Author(s), under exclusive licence to CPS and SIMM.

Entities:  

Keywords:  Vps33b; bile acids; cholestasis; liver injury; metabonomics

Mesh:

Substances:

Year:  2021        PMID: 34253877      PMCID: PMC8975861          DOI: 10.1038/s41401-021-00723-3

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  30 in total

1.  p53-mediated regulation of bile acid disposition attenuates cholic acid-induced cholestasis in mice.

Authors:  Pan Chen; Dongshun Li; Yixin Chen; Jiahong Sun; Kaili Fu; Lihuan Guan; Huizhen Zhang; Yiming Jiang; Xi Li; Xuezhen Zeng; Xiao Chen; Min Huang; Huichang Bi
Journal:  Br J Pharmacol       Date:  2017-10-22       Impact factor: 8.739

2.  ARC syndrome with high GGT cholestasis caused by VPS33B mutations.

Authors:  Jian-She Wang; Jing Zhao; Li-Ting Li
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

3.  Hepatic levels of bile acids in end-stage chronic cholestatic liver disease.

Authors:  S Fischer; U Beuers; U Spengler; F M Zwiebel; H G Koebe
Journal:  Clin Chim Acta       Date:  1996-07-30       Impact factor: 3.786

4.  Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis.

Authors:  S Teng; M Piquette-Miller
Journal:  Br J Pharmacol       Date:  2007-04-16       Impact factor: 8.739

5.  Vacuolar Protein Sorting 33B Is a Tumor Suppressor in Hepatocarcinogenesis.

Authors:  Conghui Wang; Yuqiang Cheng; Xiuping Zhang; Nan Li; Lin Zhang; Shengdian Wang; Xuemei Tong; Ying Xu; Guo-Qiang Chen; Shuqun Cheng; Xuemei Fan; Junling Liu
Journal:  Hepatology       Date:  2018-11-05       Impact factor: 17.425

Review 6.  Bile acid metabolism and signaling.

Authors:  John Y L Chiang
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

7.  Low dose of oleanolic acid protects against lithocholic acid-induced cholestasis in mice: potential involvement of nuclear factor-E2-related factor 2-mediated upregulation of multidrug resistance-associated proteins.

Authors:  Pan Chen; Hang Zeng; Yongtao Wang; Xiaomei Fan; Chenshu Xu; Rongrong Deng; Xunian Zhou; Huichang Bi; Min Huang
Journal:  Drug Metab Dispos       Date:  2014-02-07       Impact factor: 3.922

8.  PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update.

Authors:  Xiaowei Wang; Athanasia Spandidos; Huajun Wang; Brian Seed
Journal:  Nucleic Acids Res       Date:  2011-11-15       Impact factor: 16.971

9.  Vps33b is crucial for structural and functional hepatocyte polarity.

Authors:  Joanna Hanley; Dipok Kumar Dhar; Francesca Mazzacuva; Rebeca Fiadeiro; Jemima J Burden; Anne-Marie Lyne; Holly Smith; Anna Straatman-Iwanowska; Blerida Banushi; Alex Virasami; Kevin Mills; Frédéric P Lemaigre; A S Knisely; Steven Howe; Neil Sebire; Simon N Waddington; Coen C Paulusma; Peter Clayton; Paul Gissen
Journal:  J Hepatol       Date:  2017-01-09       Impact factor: 25.083

Review 10.  Cholestatic liver diseases: new targets, new therapies.

Authors:  Priscila Santiago; Andrew R Scheinberg; Cynthia Levy
Journal:  Therap Adv Gastroenterol       Date:  2018-08-24       Impact factor: 4.409

View more
  3 in total

1.  One case of arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome featuring an incomplete and mild phenotype.

Authors:  Lianhu Yu; Dan Li; Ting Zhang; Yongmei Xiao; Yizhong Wang; Ting Ge
Journal:  BMC Nephrol       Date:  2022-06-27       Impact factor: 2.585

2.  Screening of Biomarkers and Toxicity Mechanisms of Rifampicin-Induced Liver Injury Based on Targeted Bile Acid Metabolomics.

Authors:  Yang Deng; Xilin Luo; Xin Li; Yisha Xiao; Bing Xu; Huan Tong
Journal:  Front Pharmacol       Date:  2022-06-10       Impact factor: 5.988

3.  Bile Acid Regulates the Colonization and Dissemination of Candida albicans from the Gastrointestinal Tract by Controlling Host Defense System and Microbiota.

Authors:  Shankar Thangamani; Ross Monasky; Jung Keun Lee; Vijay Antharam; Harm HogenEsch; Tony R Hazbun; Yan Jin; Haiwei Gu; Grace L Guo
Journal:  J Fungi (Basel)       Date:  2021-11-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.